Navigation Links
Cell Biosciences Launches Unique Protein Phosphorylation Assay Service
Date:9/1/2009

SANTA CLARA, Calif., Sept. 1 /PRNewswire/ -- Cell Biosciences, Inc. today launched a service program to provide phosphoprotein analysis of pre-clinical samples for pharmaceutical and biotechnology companies. Under the Cell Biosciences Focus Assay Service program, client companies receive detailed analytical information about cell signaling proteins in their specimens. This information provides insight into disease processes and aids in the development of new treatments. The service will be performed using the Cell Biosciences CB1000 system, which enables quick and quantitative analysis of critical control proteins in extremely small samples - as few as 25 cells per measurement.

"The Focus Assay Service was developed in direct response to customer needs," said Dr. Wilhelm Lachnit, Vice President of R&D and Applications at Cell Biosciences. "Since the April launch of the CB1000 system, we've received numerous requests for an analytical service offering. This technology has clearly captured the interest of researchers and we're excited to share it with more customers."

The Focus Assay Service presently features a menu of assays for proteins involved in cancer cell growth and proliferation. A custom assay development service is available for novel proteins. Each Focus project includes a dedicated project manager who directs the study from sample preparation to final presentation. "We've designed every aspect of the Focus Assay Service with the customer in mind," continued Dr. Lachnit. "This program represents a fast, affordable way to access the CB1000 technology."

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems, software, and assay products that reveal previously undetectable information about cellular control pathways. Our customers include leading inst
'/>"/>

SOURCE Cell Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences(R) to Provide World-Class Fluid Management and Liquid/Powder System Solutions
2. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
3. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
4. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
5. BD Biosciences Launches New Cell Analyzer for Complex Multicolor Experiments in Disease and Drug Development Research
6. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
7. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
8. Sangamo BioSciences Reports First Quarter 2009 Financial Results
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
10. Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
11. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... York (PRWEB) September 15, 2014 Transvaginal ... Inc. continue to move forward in the federal multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... Final Order on September 10th that provides for the ... notes that none of the affected plaintiffs has objected ...
(Date:9/15/2014)... MONDAY, Sept. 15, 2014 (HealthDay News) -- U.S. heart ... an electrocardiogram (ECG) when evaluating young people for underlying ... The American Heart Association and the American College ... more detailed personal and family medical history along with ... genetic or congenital (existing from birth) risks for sudden ...
(Date:9/15/2014)... the prospective Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer ... affecting both the front and the crown of their ... risk of developing aggressive prostate cancer (usually indicates a ... non-aggressive prostate cancer) later in life, compared to men ... other patterns of baldness and prostate cancer risk. The ...
(Date:9/15/2014)... 2014 - An estimated 8% of Americans will suffer ... during their lifetime. Brought on by an overwhelming or ... altered chemistry and physiology of the brain. Understanding how ... altered by PTSD is essential to developing effective interventions. ... at The University of Texas at Dallas published online ...
(Date:9/15/2014)... FL (PRWEB) September 15, 2014 The ... away from putting low-level offenders in jail and prison ... Group sees this shift as a positive change. , ... prescription drug and heroin abuse. According to an ... parties are calling for a shift away from using ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:Certain form of baldness at age 45 linked to higher risk of aggressive prostate cancer 2Health News:EEG study findings reveal how fear is processed in the brain 2Health News:White House Shifts Policy on Drugs 2
... body of basic animal research and studies of abused ... for the hypothesis that individuals with particular genotypes are ... with the abuse of alcohol and other substances. ... assume that these genotypes identify people who are predestined ...
... Board of Directors Audit Committee Members and Complies with ... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... J. Wilson as vice president of finance and principal ... team. She brings over twenty years of finance ...
... of Suntan Lotions, Reducing Risk of Deadly Skin Cancer ... & Prevention MonthNEW YORK, April 29 The ... people avoid overexposure to harmful ultraviolet radiation from the ... all across America reduce the risk of skin cancer ...
... 23-month-old child in Texas; CDC warns more deaths are ... 23-month-old child in Texas has become the first U.S. ... officials said Wednesday morning. , Dr. Richard Besser, acting ... Prevention, confirmed the death. No other details on the ...
... Dr. Gordon Norman presents overview of US healthcare ... Federation of Health Plans Meeting in Boston- Noted ... value for its healthcare investment- Emphasized greater coordination ... resolve today,s healthcare challenges MARIETTA, Ga., April 29 ...
... & Mentally IllNEW YORK, April 29 May marks ... it, philanthropic-minded New Yorkers will raise money for Weston ... and physically disabled. As federal and state funding ... the current economy, supporters will raise funds amidst live ...
Cached Medicine News:Health News:Genetic risk for anxiety does not have to be destiny 2Health News:PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 3Health News:U.S. Reports First Swine Flu Death 2Health News:U.S. Reports First Swine Flu Death 3Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 2Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 3Health News:Weston United Celebrates Mental Health Month on May 19th 2
(Date:9/15/2014)... Female Health Company (NASDAQ-CM: FHCO) today announced that ... as Executive Vice President of Global Operations effective September ... Pope will retire from his position as Vice ... Following his retirement, Mr. Pope will continue his affiliation ... to joining The Female Health Company (FHC), Mr. Tayler ...
(Date:9/15/2014)... 2014 Research and Markets has announced the ... report to their offering. Heart defect closure ... closure devices help when closing the ostium/ hole/ deficiency in the ... vessels that occurs in the patients with CHDs. CHD is an ... of birth, which are among the most common types of birth ...
(Date:9/15/2014)... , Sept. 15, 2014   Royal Philips  (NYSE: ... growing range of advanced women,s healthcare imaging solutions will ... for Ultrasound in Obstetrics and Gynecology (ISUOG) World Congress, ... . "We,re continually investing in ... and outcomes," said Vitor Rocha , CEO and ...
Breaking Medicine Technology:The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 2The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 3Global Heart Defect Closure Devices Market 2014-2018: Key Vendors are Boston Scientific, St. Jude Medical, W.L. Gore and Associates 2Global Heart Defect Closure Devices Market 2014-2018: Key Vendors are Boston Scientific, St. Jude Medical, W.L. Gore and Associates 3Philips Showcases Ultrasound Innovations that Address Clinical Challenges in the OB/GYN Segment at ISUOG World Congress 2Philips Showcases Ultrasound Innovations that Address Clinical Challenges in the OB/GYN Segment at ISUOG World Congress 3
... vascular closure device quickly seals ... procedures, allowing for early ambulation ... creates a mechanical seal by ... bio-absorbable anchor and collagen sponge, ...
These are coronary angiographic catheters used for selective coronary bypass angiography. The catheters curve configuration is ideally suited to select the internal mammary artery....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: